Fluidigm Corporation (FLDM) 8.80 $FLDM
Fluidigm Introduces New High-Throughput Targeted NGS Library Preparation System
GlobeNewswire - Thu Aug 04, 3:15PM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced the launch of the Juno(TM) Targeted DNA Sequencing Library Preparation System, the industry's most scalable automated library preparation solution for medium-to-high-throughput next-generation sequencing (NGS). Bringing together the proven Fluidigm(R) Juno microfluidic automation platform with the benefits of multiplexed target amplification, laboratories can accurately sequence more samples faster and more affordably than ever before.
FLDM: 8.80 (+0.01)
Fluidigm Recieves ISO 13485 and ISO 9001 Certification at San Francisco and Singapore Facilities
GlobeNewswire - Thu Aug 04, 3:15PM CDT
Fluidigm Corporation (NASDAQ:FLDM), a pioneer in single-cell analysis, today announced the company has received ISO 13485:2003 and ISO 9001:2008 certification for the design, development, manufacturing and distribution of single-cell genomics and high-throughput genomics systems. The certified San Francisco facility designs and develops instrumentation, IFCs, reagents, and software, and manufactures high-performance genomic reagents and conjugated antibodies. The certified Singapore facility manufactures Fluidigm instruments and integrated fluidic circuits (IFCs) for comprehensive analysis of single cells and nucleic acids from blood, tissues, and tumor samples.
FLDM: 8.80 (+0.01)
Fluidigm Appoints New President and Chief Operating Officer
GlobeNewswire - Thu Aug 04, 3:08PM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Chris Linthwaite as President and Chief Operating Officer. Reporting directly to the Chief Executive Officer Gajus Worthington, Linthwaite will oversee all worldwide business operations including sales, marketing, research and development, manufacturing and quality.
FLDM: 8.80 (+0.01)
Fluidigm Announces Second Quarter Financial Results
GlobeNewswire - Thu Aug 04, 3:03PM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the second quarter ended June 30, 2016.
FLDM: 8.80 (+0.01)
Fluidigm to Announce Q2 2016 Financial Results and Host Conference Call for Investors
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced it will report second quarter 2016 financial results on Thursday, August 4, 2016, after the financial markets close.
FLDM: 8.80 (+0.01)
Fluidigm Announces New Customer Inspiration Center in Canada for Mass Cytometry
GlobeNewswire - Thu Jun 09, 8:00AM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced the opening of a new customer inspiration center in Markham, Ontario, Canada. Providing researchers with firsthand experience on the Helios(TM) system, the latest mass cytometry instrument using CyTOF technology, the customer inspiration center will be open to investigators around the world seeking to incorporate mass cytometry in their own research laboratories.
FLDM: 8.80 (+0.01)
Fluidigm Introduces Single-Cell TCR Sequencing on the C1 System at Immunology 2016(TM)
GlobeNewswire - Mon May 16, 8:00AM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of Single-Cell TCR Sequencing, a new immunology application on the C1(TM) system that enables in-depth profiling of T cells at single-cell resolution. Uncovering the unique T cell receptor (TCR) alpha and beta chains from each cell in conjunction with the corresponding gene expression signature, Single-Cell TCR Sequencing provides researchers with a novel approach to interrogate the functional response of each T cell. This information can provide new insights into the biological mechanisms that govern the body's response to infectious disease, the regulation of autoimmune or allergic reactions and the development of effective immunotherapies.
FLDM: 8.80 (+0.01)
Fluidigm reports 1Q loss
Automated Insights - Thu May 05, 8:53AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Fluidigm Corp. (FLDM) on Thursday reported a loss of $19.9 million in its first quarter.
FLDM: 8.80 (+0.01)
Fluidigm Announces First Quarter Financial Results
GlobeNewswire - Thu May 05, 6:25AM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the first quarter ended March 31, 2016.
FLDM: 8.80 (+0.01)
Fluidigm Announces New Integrated Fluidic Circuits for Single-Cell Genomics on the C1 System
GlobeNewswire - Tue Apr 12, 7:44AM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced new integrated fluidic circuits (IFCs) that will increase the number of single cells that can be isolated and analyzed on the C1(TM) system. Bringing together the trusted Fluidigm C1 single-cell isolation system with the benefits of a growing suite of optimized microfluidic circuits, researchers can confidently expand their single-cell studies while taking advantage of well-established, industry-proven workflows.
FLDM: 8.80 (+0.01)
Clontech Laboratories, Inc. Releases the SMART-Seq v4 Ultra Low Input RNA Kit for the Fluidigm C1 System
PR Newswire - Wed Apr 06, 12:00PM CDT
Clontech Laboratories, Inc., a wholly owned subsidiary of Takara Bio Inc., and Fluidigm Corporation today announced the recent launch of Clontech's SMART-Seq v4 Ultra Low Input RNA Kit for the Fluidigm C1 System. This kit, which is available for 4 and 10 IFCs (integrated fluidic circuits), allows high-quality cDNA synthesis starting from 96 single cells that have been isolated and processed with the Fluidigm C1 System, using a script available in the Fluidigm Script Hub.
FLDM: 8.80 (+0.01)
Fluidigm Q4 Loss Narrower than Expected, Revenues Fall Y/Y
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 11:20AM CST
Fluidigm reported adjusted loss of 38 cents per share in fourth-quarter 2015, narrower than the Zacks Consensus Estimate of 48 cents.
ABMD: 117.43 (-0.20), FLDM: 8.80 (+0.01), LMNX: 21.12 (+0.19), CRY: 16.23 (+0.39)
Fluidigm Announces Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Thu Feb 04, 3:00PM CST
Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the fourth quarter and full year ended December 31, 2015.
FLDM: 8.80 (+0.01)
Fluidigm to Announce Q4-Full Year 2015 Financial Results and Host Conference Call for Investors
GlobeNewswire - Thu Jan 28, 4:30PM CST
Fluidigm Corporation (NASDAQ:FLDM) will report its fourth quarter and full year 2015 financial results on February 4, 2016, after close of market.
FLDM: 8.80 (+0.01)
Global Liquid Biopsy Markets Market Size, Strategies and Forecasts 2016 to 2020
M2 - Tue Jan 26, 4:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/v2x28v/liquid_biopsy) has announced the addition of the "Liquid Biopsy Markets Global Market Size, Strategies and Forecasts 2016 to 2020" report to their offering. The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening. Use independent research that makes you the expert. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers. What is the size of the huge screening opportunity? Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Liquid Biopsy Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. Potential Market Opportunity Sizes Companies Mentioned - ASCO - AdnaGen (now Qiagen) - Agena Bioscience - Angle plc - ApoCell - AstraZeneca - Baylor - Bio-Rad Laboratories - BioFluidica - Biocept - Biodesix - Boreal Genomics - Broad Institute - CRUK Manchester Institute - Chronix Biomedical - Clearbridge BioMedics - Cynvenio - CytoTrack - Cytolumina Technologies Corp - Diagnologix LLC - Epic Sciences - Exosome - Fluidigm Corp - Fluxion Biosciences - GRAIL - Genomic Health - Guardant Health - HTG Molecular Diagnostics - HansaBiomed - Horizon Discovery - Illumina - Inivata - Janssen Diagnostics - Merck Serono - Molecular MD For more information visit http://www.researchandmarkets.com/research/v2...uid_biopsy
FLDM: 8.80 (+0.01), MRK: 62.98 (+0.08), HTGM: 2.71 (+0.06), GHDX: 27.12 (+0.45)
Fluidigm's Q4 Preliminary Results Fail to Woo Investors
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 12:40PM CST
Market is not really upbeat about Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter of 2015.
FLDM: 8.80 (+0.01), BIO: 151.14 (+1.65), ILMN: 167.90 (-0.66), EXAC: 27.90 (+0.10)
Accuray Expands EIMEA Footprint with New Installations
Zacks Equity Research - Zacks Investment Research - Fri Jan 15, 12:10PM CST
Accuray Inc. (ARAY) recently installed CyberKnife M6 system in Qatar and Latvia.
ABMD: 117.43 (-0.20), FLDM: 8.80 (+0.01), EXAC: 27.90 (+0.10), ARAY: 5.42 (+0.12)
Fluidigm Introduces New High-Throughput Targeted NGS Library Preparation System
GlobeNewswire - Thu Aug 04, 3:15PM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced the launch of the Juno(TM) Targeted DNA Sequencing Library Preparation System, the industry's most scalable automated library preparation solution for medium-to-high-throughput next-generation sequencing (NGS). Bringing together the proven Fluidigm(R) Juno microfluidic automation platform with the benefits of multiplexed target amplification, laboratories can accurately sequence more samples faster and more affordably than ever before.
FLDM: 8.80 (+0.01)
Fluidigm Recieves ISO 13485 and ISO 9001 Certification at San Francisco and Singapore Facilities
GlobeNewswire - Thu Aug 04, 3:15PM CDT
Fluidigm Corporation (NASDAQ:FLDM), a pioneer in single-cell analysis, today announced the company has received ISO 13485:2003 and ISO 9001:2008 certification for the design, development, manufacturing and distribution of single-cell genomics and high-throughput genomics systems. The certified San Francisco facility designs and develops instrumentation, IFCs, reagents, and software, and manufactures high-performance genomic reagents and conjugated antibodies. The certified Singapore facility manufactures Fluidigm instruments and integrated fluidic circuits (IFCs) for comprehensive analysis of single cells and nucleic acids from blood, tissues, and tumor samples.
FLDM: 8.80 (+0.01)
Fluidigm Appoints New President and Chief Operating Officer
GlobeNewswire - Thu Aug 04, 3:08PM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Chris Linthwaite as President and Chief Operating Officer. Reporting directly to the Chief Executive Officer Gajus Worthington, Linthwaite will oversee all worldwide business operations including sales, marketing, research and development, manufacturing and quality.
FLDM: 8.80 (+0.01)
Fluidigm Announces Second Quarter Financial Results
GlobeNewswire - Thu Aug 04, 3:03PM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the second quarter ended June 30, 2016.
FLDM: 8.80 (+0.01)
Fluidigm to Announce Q2 2016 Financial Results and Host Conference Call for Investors
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced it will report second quarter 2016 financial results on Thursday, August 4, 2016, after the financial markets close.
FLDM: 8.80 (+0.01)
Fluidigm Announces New Customer Inspiration Center in Canada for Mass Cytometry
GlobeNewswire - Thu Jun 09, 8:00AM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced the opening of a new customer inspiration center in Markham, Ontario, Canada. Providing researchers with firsthand experience on the Helios(TM) system, the latest mass cytometry instrument using CyTOF technology, the customer inspiration center will be open to investigators around the world seeking to incorporate mass cytometry in their own research laboratories.
FLDM: 8.80 (+0.01)
Fluidigm Introduces Single-Cell TCR Sequencing on the C1 System at Immunology 2016(TM)
GlobeNewswire - Mon May 16, 8:00AM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of Single-Cell TCR Sequencing, a new immunology application on the C1(TM) system that enables in-depth profiling of T cells at single-cell resolution. Uncovering the unique T cell receptor (TCR) alpha and beta chains from each cell in conjunction with the corresponding gene expression signature, Single-Cell TCR Sequencing provides researchers with a novel approach to interrogate the functional response of each T cell. This information can provide new insights into the biological mechanisms that govern the body's response to infectious disease, the regulation of autoimmune or allergic reactions and the development of effective immunotherapies.
FLDM: 8.80 (+0.01)
Fluidigm reports 1Q loss
Automated Insights - Thu May 05, 8:53AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Fluidigm Corp. (FLDM) on Thursday reported a loss of $19.9 million in its first quarter.
FLDM: 8.80 (+0.01)
Fluidigm Announces First Quarter Financial Results
GlobeNewswire - Thu May 05, 6:25AM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the first quarter ended March 31, 2016.
FLDM: 8.80 (+0.01)
Fluidigm Announces New Integrated Fluidic Circuits for Single-Cell Genomics on the C1 System
GlobeNewswire - Tue Apr 12, 7:44AM CDT
Fluidigm Corporation (NASDAQ:FLDM) today announced new integrated fluidic circuits (IFCs) that will increase the number of single cells that can be isolated and analyzed on the C1(TM) system. Bringing together the trusted Fluidigm C1 single-cell isolation system with the benefits of a growing suite of optimized microfluidic circuits, researchers can confidently expand their single-cell studies while taking advantage of well-established, industry-proven workflows.
FLDM: 8.80 (+0.01)
Clontech Laboratories, Inc. Releases the SMART-Seq v4 Ultra Low Input RNA Kit for the Fluidigm C1 System
PR Newswire - Wed Apr 06, 12:00PM CDT
Clontech Laboratories, Inc., a wholly owned subsidiary of Takara Bio Inc., and Fluidigm Corporation today announced the recent launch of Clontech's SMART-Seq v4 Ultra Low Input RNA Kit for the Fluidigm C1 System. This kit, which is available for 4 and 10 IFCs (integrated fluidic circuits), allows high-quality cDNA synthesis starting from 96 single cells that have been isolated and processed with the Fluidigm C1 System, using a script available in the Fluidigm Script Hub.
FLDM: 8.80 (+0.01)
Fluidigm Q4 Loss Narrower than Expected, Revenues Fall Y/Y
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 11:20AM CST
Fluidigm reported adjusted loss of 38 cents per share in fourth-quarter 2015, narrower than the Zacks Consensus Estimate of 48 cents.
ABMD: 117.43 (-0.20), FLDM: 8.80 (+0.01), LMNX: 21.12 (+0.19), CRY: 16.23 (+0.39)
Fluidigm Announces Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Thu Feb 04, 3:00PM CST
Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the fourth quarter and full year ended December 31, 2015.
FLDM: 8.80 (+0.01)
Fluidigm to Announce Q4-Full Year 2015 Financial Results and Host Conference Call for Investors
GlobeNewswire - Thu Jan 28, 4:30PM CST
Fluidigm Corporation (NASDAQ:FLDM) will report its fourth quarter and full year 2015 financial results on February 4, 2016, after close of market.
FLDM: 8.80 (+0.01)
Global Liquid Biopsy Markets Market Size, Strategies and Forecasts 2016 to 2020
M2 - Tue Jan 26, 4:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/v2x28v/liquid_biopsy) has announced the addition of the "Liquid Biopsy Markets Global Market Size, Strategies and Forecasts 2016 to 2020" report to their offering. The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening. Use independent research that makes you the expert. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers. What is the size of the huge screening opportunity? Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Liquid Biopsy Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. Potential Market Opportunity Sizes Companies Mentioned - ASCO - AdnaGen (now Qiagen) - Agena Bioscience - Angle plc - ApoCell - AstraZeneca - Baylor - Bio-Rad Laboratories - BioFluidica - Biocept - Biodesix - Boreal Genomics - Broad Institute - CRUK Manchester Institute - Chronix Biomedical - Clearbridge BioMedics - Cynvenio - CytoTrack - Cytolumina Technologies Corp - Diagnologix LLC - Epic Sciences - Exosome - Fluidigm Corp - Fluxion Biosciences - GRAIL - Genomic Health - Guardant Health - HTG Molecular Diagnostics - HansaBiomed - Horizon Discovery - Illumina - Inivata - Janssen Diagnostics - Merck Serono - Molecular MD For more information visit http://www.researchandmarkets.com/research/v2...uid_biopsy
FLDM: 8.80 (+0.01), MRK: 62.98 (+0.08), HTGM: 2.71 (+0.06), GHDX: 27.12 (+0.45)
Fluidigm's Q4 Preliminary Results Fail to Woo Investors
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 12:40PM CST
Market is not really upbeat about Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter of 2015.
FLDM: 8.80 (+0.01), BIO: 151.14 (+1.65), ILMN: 167.90 (-0.66), EXAC: 27.90 (+0.10)
Accuray Expands EIMEA Footprint with New Installations
Zacks Equity Research - Zacks Investment Research - Fri Jan 15, 12:10PM CST
Accuray Inc. (ARAY) recently installed CyberKnife M6 system in Qatar and Latvia.
ABMD: 117.43 (-0.20), FLDM: 8.80 (+0.01), EXAC: 27.90 (+0.10), ARAY: 5.42 (+0.12)
